Johnson & Johnson (JNJ): Reliable Today — But Facing Shifts Beneath the Surface

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886, renowned for its development of medical devices, pharmaceuticals, and consumer healthcare products. A component of the Dow Jones Industrial Average, J&J ranked No. 36 on the 2021 Fortune 500 list of the largest U.S. corporations by total revenue. As one of the world’s most valuable companies, it holds one of only two AAA credit ratings among U.S.-based corporations—higher even than the U.S. government.

Johnson & Johnson (JNJ) operates with a longstanding commitment to innovation and resilience. It boasts a profit margin of 69.1% and offers an attractive dividend yield of 3.0%. The company’s market capitalization stands at 403.0B USD, underscoring its status as a mature and stable blue-chip stock.

According to AAOIFI’s Shariah compliance standards, Johnson & Johnson is considered COMPLIANT based on the most recent financial data. JNJ operates in a Halal-compliant industry. The interest income ratio is 1.50%, well within the 5% threshold. The interest-bearing debts ratio stands at 10.52%, and its liquid assets ratio at 11.19%—both comfortably within the 30% ceiling. To confirm the current Halal compliance status, please log in to purepofo.com.

Over the years, Johnson & Johnson has consistently upheld Halal standards, reinforcing investor confidence.

Beyond numerical thresholds, ethical alignment plays a vital role in Halal investing. J&J has not been flagged by users for involvement in controversial or unethical activities and remains COMPLIANT based on user-driven ethical indicators.

Halal investing is not just about compliance today — it’s about anticipating risks tomorrow. purepofo’s forward-looking AI combines Shariah standards with predictive insight, allowing investors to protect their portfolios with foresight and integrity. Our forecasts are powered by a Random Forest model trained on 13 years of data across more than 5,000 stocks. Johnson & Johnson is forecasted to maintain its compliant status going forward.

JNJ’s revenue growth of 5.4% indicates a measured pace in Market Expansion, consistent with its Maturity profile. A net income decline of -11.5% reflects pressure in Income Growth. Margin trends also remain under stress, with a gross margin trend of -0.1% and an EBIT margin trend of -2.5%, pointing to profitability headwinds. On a more positive note, its Reinvestment Capacity is supported by a solid free cashflow trend of 7.2%. However, a share price contraction of -9.9% reflects weakness in Price Confidence.

Revenue variation of 3.45 suggests inconsistency in Revenue Stability, while profit margin variation of 0% affirms strong Profit Stability. A free cashflow yield of 4.6% highlights strength in Financial Strength. JNJ’s dividend growth of 0.6% reflects sustained, albeit modest, Dividend Trend. A dividend yield of 3.0% reinforces JNJ’s strong performance in Dividend Yield—an attractive feature for income-focused investors.

JNJ’s Altman Z-score is not available, but its low net debt to EBITDA ratio of 0.51 affirms Financial Robustness. Its strong free cashflow deviation of 8.8% highlights consistent Cashflow Stability. The dividend payout ratio of 84.1% underscores stable Payout Quality. Stock price volatility of 1.3% reflects strength in Price Fluctuation, and a maximum drawdown of 12.7% indicates resilience in Price Risks.

We don’t just rate how a company performed. We predict how it may perform next. purepofo’s lifecycle model helps investors build ahead with confidence.

Johnson & Johnson demonstrates notable investment strengths in the following areas: its stock price volatility (standard deviation) of 1.3% confirms strong performance in Price Fluctuation. Consistency in cash generation is evident through a free cashflow deviation of just 8.8%. Its Reinvestment Capacity is further supported by a robust free cashflow trend of 7.2%. These attributes reflect JNJ’s mature, low-risk investment appeal.

We identified the following key risks for Johnson & Johnson: a decline in net income growth (-11.5%) signals underperformance in Income Growth. Margin pressure is evident in both the gross margin trend (-0.1%) and EBIT margin trend (-2.5%), suggesting challenges in sustaining Profitability. These areas merit ongoing monitoring.

Johnson & Johnson exhibits a Maturity profile based on purepofo’s weighted Business Lifecycle score, combining long-term stability with consistent income generation and risk-managed fundamentals.